The Impact of Human Serum on ADCC Assays

3rd July 2018

Category: Bioanalytical

Tags: ,

By: Laura McAleer, Technical Services Scientist,

Antibody-Dependent Cellular Cytotoxicity (ADCC) is a mechanism adopted by the immune system to remove infected or cancerous cells. Antibodies bind a specific antigen on the target cell surface, which in turn binds the FcγRIIIa receptor on effector cells (e.g Natural Killer (NK) Cells) via the Fc region, resulting in the lysis of the target cell. Although in More

Qualifying & Developing VEGF Binding Assay using an iQue® Screener PLUS

25th May 2018

Category: Bioanalytical

By: Ben Tyrrell - Scientist, Katie Chapple - Scientist,

The iQue® Screener PLUS, by Intellicyt (part of the Sartorius Group), is used at Sartorius Stedim BioOutsource to achieve a faster assay throughput and deliver an air-gap-deliminated flow of samples to the detectors. Bevacizumab is a humanized monoclonal antibody (mAb) which mediates its activity through a high affinity binding to VEGF (vascular endothelial growth factor). More

Robust & Reproducible ADCC with Single Donor KILR CD16 Effector Cells

23rd May 2018

Category: Bioanalytical

By: Laura McAleer, Technical Services Scientist, Lisa Blackwood - Scientist,

The success of ADCC (antibody-dependent cell-mediated cytotoxicity) depends on the quality of the effector cells used. Traditional ADCC assays can be complex and require freshly isolated primary human cells, such as PBMC (peripheral blood mononuclear cell) or NK (natural killer) cells. However these can have inter-individual variability. While NK cell lines engineered to overexpress CD16 are More

The Path to Protein Concentration Measurement

8th May 2018

Category: Bioanalytical

Tags: , ,

By: Stuart Wright - Scientist,

Protein Concentration Analysis Quick and accurate measurement of protein concentration is very important within the biopharmaceutical industry. This must be carried out on a large number of samples prior to performing the various physicochemical analysis involved in protein characterization or protein structural analysis, since many assays depend on knowledge of the biotherapeutic protein concentration. However, More

Orthogonal Chromatographic Techniques for Therapeutic Protein Characterization

1st March 2018

Category: Bioanalytical

Tags: , ,

By: Stuart Wright - Scientist,

Development of biotherapeutics, for example monoclonal antibodies (mAbs), requires a wide range of physicochemical and structural analysis to be undertaken in accordance with ICH Q6B guidelines. Each technique will assess different critical quality attributes (CQAs) which form part of the analytical characterization of the biotherapeutic. CQAs are properties or characteristics relating to physical, chemical, biological More

Characterization of Protein Structure: The Value of Intact Mass Analysis

26th February 2018

Category: Bioanalytical

Tags: , ,

By: Dr Martin De Cecco - Senior Scientist,

Intact mass analysis is the assessment of a protein’s total molecular weight  by mass spectrometry (MS) without prior digestion or fragmentation of the molecule of interest. Molecular weight determination forms part of the ICH Q6B guidelines for physicochemical analysis of biological products: what use is this information in the analytical characterization of biopharmaceuticals? High resolution More

Why Glycan Analysis is an Essential Part of Therapeutic Protein Characterization

4th January 2018

Category: Bioanalytical

By: Dr Martin De Cecco - Senior Scientist,

A recent report on the growth of the glycan analysis market¹ highlighted the importance of assessing the glycosylation of biotherapeutics. The carbohydrate structures attached to the crystallizable fragment (Fc) of monoclonal antibodies can influence efficacy and safety and so they are often classed as critical quality attributes. For this reason the analytical characterization of glycosylation More

Improved Product Quality of Biosimilars in the Cellca CHO Expression Platform

15th December 2017

Category: Biosimilars

Tags: ,

By: Cornelia Lindner - Team Leader, Dr Christoph Zehe - Lead Scientist, Johannes Wirth - Scientist, Marina Putanko - Scientist,

Due to the high number of patent expirations for first generation biopharmaceuticals, the production of biosimilars is a fast growing market. Biosimilars require finger-print like similarity to their originator drug with respect to product quality.  One important aspect of product quality is a comparable glycosylation pattern, as glycosylation influences serum clearance, immunogenicity, as well as More

Promoter Evaluation in the Cellca CHO DG44 Expression System

4th December 2017

Category: Cell Line Development

Tags: ,

By: Ann-Catherin Leroux - Scientist, Dr Christoph Zehe - Lead Scientist,

One key component of the powerful Cellca Expression Platform is the expression vector. We have carefully selected its genetic elements to allow: freedom to operate high level expression of monomeric and dimeric products (e.g. IgG-type antibodies, Fc-Fusion, bispecifics) enhanced, stable expression by optimized S/MAR elements increased secretion by optimized signal peptide As a next step More

Improved Speed to Clinic by Increasing Automation in Cell Line Development

14th November 2017

Category: Cell Line Development

Tags: , ,

By: Dr Christoph Zehe - Lead Scientist, Dr Monika Holeiter - Senior Scientist, Technology Development,

“Speed to Clinic” is a crucial measure for successful drug development. As a leading provider of stable cell lines, Sartorius Stedim Cellca strives to contribute to this goal by increasing the degree of automation in its Cell Line Development (CLD) technology. While maintaining consistently high quality of the recombinant products, we develop an automation strategy More

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

Sign-up to receive 3 tips on improving
speed to clinic for biosimilars

* you agree to receive emails with tips, news, insights and quizzes.